This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Quest Diagnostics says plaintiffs should not be given another chance in allergy testing, immunotherapy antitrust case

( April 5, 2019, 22:31 GMT | Official Statement) -- MLex Summary: Quest Diagnostics has filed an opposition to United Allergy Services and the Academy of Allergy and Asthma Primary Care’s motion to alter or amend a judgment that dismissed their case accusing Quest of conspiring to eliminate competition and monopolize the markets for allergy testing and immunotherapy. Quest says UAS and AAAPC fail to “demonstrate a manifest error of law or fact as would be required for this Court to reverse its well-reasoned decision.”See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections